Search results
Results From The WOW.Com Content Network
Future Medicinal Chemistry is a peer-reviewed medical journal covering all aspects of medicinal chemistry, including drug discovery, pharmacology, in silico drug design, structural characterization techniques, ADME-Tox investigations, and science policy, economic and intellectual property issues. It was established in 2009 and is published by ...
The term in silico was first used in 1989 at a workshop "Cellular Automata: Theory and Applications" by a mathematician from National Autonomous University of Mexico (UNAM). [2] The term in silico radiation oncology, a precursor of generic in silico medicine was coined and first introduced by G. Stamatakos in Proceedings of the IEEE in 2002. [3]
Accurate computer models of a treatment and its deployment, as well as patient characteristics, are necessary precursors for the development of in silico clinical trials. [5] [6] [8] [9] In such a scenario, ‘virtual’ patients would be given a ‘virtual’ treatment, enabling observation through a computer simulation of how the candidate biomedical product performs and whether it produces ...
In biology and other experimental sciences, an in silico experiment is one performed on a computer or via computer simulation software. The phrase is pseudo-Latin for 'in silicon' (correct Latin : in silicio ), referring to silicon in computer chips.
Insilico Medicine is a biotechnology company headquartered in Boston, Massachusetts, [2] with additional facilities in Pak Shek Kok, Hong Kong in Hong Kong Science Park near the Chinese University of Hong Kong, [3] and in New York, at The Cure by Deerfield.
The phrase "drug design" is similar to ligand design (i.e., design of a molecule that will bind tightly to its target). [6] Although design techniques for prediction of binding affinity are reasonably successful, there are many other properties, such as bioavailability, metabolic half-life, and side effects, that first must be optimized before a ligand can become a safe and effictive drug.
The impact factor relates to a specific time period; it is possible to calculate it for any desired period. For example, the JCR also includes a five-year impact factor, which is calculated by dividing the number of citations to the journal in a given year by the number of articles published in that journal in the previous five years. [14] [15]
As of 2023, Annual Review of Pharmacology and Toxicology is being published as open access, under the Subscribe to Open model. [1] As of 2024, Journal Citation Reports lists the journal's 2023 impact factor as 11.2, ranking it second of 106 journal titles in the category "Toxicology" and ninth of 354 titles in the category "Pharmacology ...